View Older Stories View More Recent Stories

Aug 4, 2020 04:05PM Cadent Therapeutics to Present at the William Blair Biotech Focus Conference
Aug 4, 2020 08:08AM Triplet Therapeutics To Present at Upcoming Events
Aug 3, 2020 07:00AM Dyne Therapeutics Appoints Susanna High as Chief Operating Officer
Jul 23, 2020 06:00AM Triplet Therapeutics Appoints Alan Buckler, Ph.D., as Chief Scientific Officer
Jul 22, 2020 12:46PM LeadingBiotech's Boston CEO&BD Conference Joins BioPharm America™ for a Must-Attend September Event
Jul 21, 2020 08:00AM Triplet Therapeutics Selects Clinical Candidate for Novel Treatment of Repeat Expansion Disorders
Jul 20, 2020 08:00AM Dyne Therapeutics Announces Appointment of Leading DMD Expert Francesco Muntoni to Scientific Advisory Board
Jul 14, 2020 04:35PM Form SC 13D Magenta Therapeutics, Filed by: Atlas Venture Fund X, L.P.
Jul 13, 2020 07:06PM Form 3 Magenta Therapeutics, For: Jun 29 Filed by: Atlas Venture Associates Opportunity I, L.P.
Jul 7, 2020 06:55PM Form 4 Replimune Group, Inc. For: Jul 02 Filed by: Atlas Venture Fund X, L.P.
Jul 7, 2020 05:12PM Form SC 13D/A Replimune Group, Inc. Filed by: Atlas Venture Fund X, L.P.
Jul 6, 2020 10:17AM Unum Therapeutics Inc. (UMRX) Announces Acquisition of Kiq LLC
Jul 6, 2020 10:16AM Unum Therapeutics Inc. Announces Acquisition of Kiq LLC
Jun 29, 2020 07:00AM Cadent Therapeutics to Participate in Upcoming Investor Conferences
Jun 23, 2020 01:00PM Claranova: Group Management and Governance Strengthened to Accelerate a New Expansion Phase
Jun 22, 2020 09:00AM Ikena Oncology Presents New Preclinical Data Highlighting the Anti-Cancer Effects of TEAD Inhibition on the Hippo Signaling Pathway
Jun 19, 2020 05:04PM Form SC 13D/A Replimune Group, Inc. Filed by: Atlas Venture Fund X, L.P.
Jun 18, 2020 05:28PM Form 4 Generation Bio Co. For: Jun 16 Filed by: Atlas Venture Associates Opportunity I, L.P.
Jun 18, 2020 04:37PM Form 4 Replimune Group, Inc. For: Jun 16 Filed by: Atlas Venture Fund X, L.P.
Jun 17, 2020 08:00AM Harvard Business School Introduces 2020-2021 Blavatnik Fellows in Life Science Entrepreneurship
Jun 11, 2020 08:38PM Form 3 Generation Bio Co. For: Jun 11 Filed by: Atlas Venture Associates Opportunity I, LLC
Jun 11, 2020 08:00AM Dyne Therapeutics Appoints Daniel Wilson as Vice President, Head of Intellectual Property
Jun 11, 2020 06:30AM Praxis Precision Medicines Promotes Business Leader Stuart Chaffee to Chief Financial Officer
Jun 8, 2020 07:00AM Affinia Therapeutics Announces Appointment of Elliott Sigal, M.D., Ph.D. to the Company’s Board of Directors
Jun 8, 2020 07:00AM Affinia Therapeutics Announces Appointment of Elliott Sigal, M.D., Ph.D. to the Company’s Board of Directors
Jun 5, 2020 06:00AM Atlas Venture Announces $400 Million Fund XII and Expansion of Partnership
Jun 4, 2020 04:09PM Form D Atlas Venture Fund XII,
May 27, 2020 04:05PM Cadent Therapeutics to Present at the Jefferies Healthcare Conference
May 27, 2020 10:00AM Triplet Therapeutics Initiates SHIELD HD Natural History Study of Huntington’s Disease
May 27, 2020 09:00AM The Friedreich’s Ataxia Research Alliance Hires Barbara Tate, Ph.D. as FARA's New Chief Scientific Officer
May 27, 2020 07:00AM Q32 Bio Launches to Develop Novel Therapeutics Targeting Regulators of Innate and Adaptive Immunity
May 21, 2020 07:00AM HotSpot Therapeutics Completes $65 Million Series B Financing to Advance Pipeline of Novel Allosteric Medicines
May 19, 2020 08:00AM Dyne Therapeutics Accelerates Programs in Facioscapulohumeral Muscular Dystrophy (FSHD) with Exclusive Licensing of Technologies to Target Genetic Basis of FSHD and Expanded Scientific Advisory Board
May 15, 2020 10:36AM Seelos Therapeutics (SEEL) Announces Judith Dunn to Board
May 15, 2020 10:30AM Seelos Therapeutics Announces Appointment of Judith Dunn to the Board of Directors
May 15, 2020 10:30AM Seelos Therapeutics Announces Appointment of Judith Dunn to the Board of Directors
May 12, 2020 07:00AM Dyne Therapeutics Demonstrates FORCE™ Platform’s Potential to Deliver Potent Exon-Skipping Molecules Directly to Muscle to Treat Duchenne Muscular Dystrophy
May 11, 2020 08:00AM Dyne Therapeutics Announces Appointment of Debra Feldman as Vice President, Head of Regulatory
May 7, 2020 06:16AM Form 13F-HR Atlas Venture Associates For: Mar 31
May 7, 2020 06:15AM Form 13F-NT ATLAS VENTURE FUND VI For: Mar 31
May 7, 2020 06:15AM Form 13F-HR Atlas Venture Advisors, For: Mar 31
May 7, 2020 06:14AM Form 13F-NT Atlas Venture Associates For: Mar 31
May 7, 2020 06:12AM Form 13F-NT Atlas Venture Associates For: Mar 31
Apr 29, 2020 08:00AM Cadent Therapeutics Closes $15 Million Final Equity Tranche of Series B Financing
Apr 23, 2020 07:30AM Accent Therapeutics Announces $63 Million Series B Financing to Advance Novel, Precision Cancer Therapies Targeting RNA-Modifying Proteins
Mar 31, 2020 08:22AM Affinia Therapeutics Raises $60M in Series A Financing to Advance Rational Design AAV Platform and Transformative Gene Therapies
Mar 31, 2020 08:22AM Affinia Therapeutics Raises $60M in Series A Financing to Advance Rational Design AAV Platform and Transformative Gene Therapies
Mar 31, 2020 08:00AM Dyne Therapeutics Announces Equity Investment from CureDuchenne Ventures to Support Pioneering Approach to Restoring Muscle Health in DMD
Mar 12, 2020 05:00AM Kymera Therapeutics Announces $102 Million Series C Financing to Advance its Protein Degrader Pipeline and Platform
Mar 10, 2020 07:00AM Cadent Therapeutics Announces FDA Clearance of IND Application and Dosing of Subjects of CAD-9303 for Schizophrenia
View More Recent Stories View Older Stories